SHARED RESOURCE MANAGEMENT The Lineberger Comprehensive Cancer Center has a strong history of providing high quality and cost-effective shared resources that offer innovative services and technologies to the membership. The oversight of the SRs involves the Director, Deputy Director, and Associate Directors of the Center. Program leaders also provide valuable input and guidance on the services offered. Center members provide feedback through surveys and serve on SR active internal advisory boards for each SR. Over the last five years, this management process has provided substantial new infrastructure for the faculty including: 1) an expanded and more robust tissue- based research pipeline for correlative work, 2) new technologies such as single cell analysis, mass spec cytometer instrumentation, and a CyroEM, 3) expanded faculty SR leadership expertise in pathology and biostatistics. The financial and administrative oversight is provided by the Associate Director of Administration and his staff of 4 FTEs devoted to this endeavor. The SRs are well managed and are well used as demonstrated by these statistics: ? 97% of 2018 user-survey respondents stated the SR overall experience was excellent or good. ? 81% of LCCC Members used a Shared Resource in FY19 ? 82% of FY19 total LCCC managed-Shared Resource users were Center faculty Importantly, the SRs are cost-effective and provide exceptional value to the members. The Center requests 8% of the operating budget for the SRs from the CCSG. This is greatly leveraged through a sustained annual institutional commitment of over $10M in operational support, 37% of the total SR operating budget. The remaining SR operating budget, approximately $14.3M, is recovered by recharge mechanisms. As a result of the CCSG and institutional commitment, members receive discounts on fees, priority access and free consultative services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089825
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications